FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985608906> ?p ?o ?g. }

• W1985608906 endingPage "218" @default.
• W1985608906 startingPage "214" @default.
• W1985608906 abstract "Vinorelbine (i.v.) plus capecitabine (oral) combination therapy is active in anthracycline/taxane pretreated patients with metastatic breast cancer. Availability of oral vinorelbine provides this combination in an all-oral formulation. Two consecutive phase II trials differing only in vinorelbine administration routes evaluated their respective activities and tolerabilities in this population. In the i.v. group (n = 38) disease control was 61% (37% PR, 24% SD), median TTP 6.8 months and median survival 11.3 months. In the oral group (n = 38) disease control was 77% (5.4% CR, 34% PR, 38% SD), median TTP 7 months and median survival 10 months. G3–G4 neutropenia was more common in the oral group (p < 0.05); G2–G3 anaemia [5Jassem J. Pieńkowski T. Płuzańska A. Jelic S. Gorbunova V. Mrsic-Krmpotic Z. et al.Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.J Clin Oncol. 2001; 19: 1707-1715Crossref PubMed Scopus (286) Google Scholar] and G3 thrombocytopenia [1De Vita V.T. Hellman S. Rosenberg S.A. Cancer: principles and practice of oncology. J.B. Lippincott Co., Philadelphia1993Google Scholar] were observed only in the oral group. Although the comparison between the two regimens was not randomized, the results observed in these two consecutive phase II studies may suggest that oral and iv vinorelbine, in combination with capecitabine, can achieve similar responses in patients with metastatic breast cancer refractory to anthra–taxane combinations." @default.
• W1985608906 created "2016-06-24" @default.
• W1985608906 creator A5002495706 @default.
• W1985608906 creator A5020315458 @default.
• W1985608906 creator A5022124014 @default.
• W1985608906 creator A5041363231 @default.
• W1985608906 creator A5045432783 @default.
• W1985608906 creator A5058026551 @default.
• W1985608906 creator A5072894802 @default.
• W1985608906 creator A5086984759 @default.
• W1985608906 creator A5090055323 @default.
• W1985608906 creator A5090736062 @default.
• W1985608906 date "2010-06-01" @default.
• W1985608906 modified "2023-09-23" @default.
• W1985608906 title "Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies" @default.
• W1985608906 cites W1755746957 @default.
• W1985608906 cites W1773171357 @default.
• W1985608906 cites W1811085086 @default.
• W1985608906 cites W1828283074 @default.
• W1985608906 cites W1843618725 @default.
• W1985608906 cites W1849818006 @default.
• W1985608906 cites W1923449517 @default.
• W1985608906 cites W1939003096 @default.
• W1985608906 cites W1946638503 @default.
• W1985608906 cites W1970070403 @default.
• W1985608906 cites W1975402824 @default.
• W1985608906 cites W1976067234 @default.
• W1985608906 cites W2011002980 @default.
• W1985608906 cites W2014686358 @default.
• W1985608906 cites W2025504439 @default.
• W1985608906 cites W2027544639 @default.
• W1985608906 cites W2028697269 @default.
• W1985608906 cites W2029409133 @default.
• W1985608906 cites W2039176586 @default.
• W1985608906 cites W2048553013 @default.
• W1985608906 cites W2061549082 @default.
• W1985608906 cites W2063775957 @default.
• W1985608906 cites W2085380767 @default.
• W1985608906 cites W2086348123 @default.
• W1985608906 cites W2099658604 @default.
• W1985608906 cites W2106804959 @default.
• W1985608906 cites W2109057413 @default.
• W1985608906 cites W2115931762 @default.
• W1985608906 cites W2123732467 @default.
• W1985608906 cites W2131139696 @default.
• W1985608906 cites W2131770017 @default.
• W1985608906 cites W2135378470 @default.
• W1985608906 cites W2141447350 @default.
• W1985608906 cites W2143435580 @default.
• W1985608906 cites W2148809873 @default.
• W1985608906 cites W2158652816 @default.
• W1985608906 cites W2167805334 @default.
• W1985608906 cites W2212225357 @default.
• W1985608906 cites W2249234219 @default.
• W1985608906 cites W2283947545 @default.
• W1985608906 cites W2293688022 @default.
• W1985608906 cites W2408050101 @default.
• W1985608906 doi "https://doi.org/10.1016/j.breast.2010.01.015" @default.
• W1985608906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20167491" @default.
• W1985608906 hasPublicationYear "2010" @default.
• W1985608906 type Work @default.
• W1985608906 sameAs 1985608906 @default.
• W1985608906 citedByCount "13" @default.
• W1985608906 countsByYear W19856089062013 @default.
• W1985608906 countsByYear W19856089062014 @default.
• W1985608906 countsByYear W19856089062016 @default.
• W1985608906 countsByYear W19856089062019 @default.
• W1985608906 countsByYear W19856089062022 @default.
• W1985608906 crossrefType "journal-article" @default.
• W1985608906 hasAuthorship W1985608906A5002495706 @default.
• W1985608906 hasAuthorship W1985608906A5020315458 @default.
• W1985608906 hasAuthorship W1985608906A5022124014 @default.
• W1985608906 hasAuthorship W1985608906A5041363231 @default.
• W1985608906 hasAuthorship W1985608906A5045432783 @default.
• W1985608906 hasAuthorship W1985608906A5058026551 @default.
• W1985608906 hasAuthorship W1985608906A5072894802 @default.
• W1985608906 hasAuthorship W1985608906A5086984759 @default.
• W1985608906 hasAuthorship W1985608906A5090055323 @default.
• W1985608906 hasAuthorship W1985608906A5090736062 @default.
• W1985608906 hasBestOaLocation W19856089061 @default.
• W1985608906 hasConcept C121608353 @default.
• W1985608906 hasConcept C126322002 @default.
• W1985608906 hasConcept C141071460 @default.
• W1985608906 hasConcept C143998085 @default.
• W1985608906 hasConcept C2775930923 @default.
• W1985608906 hasConcept C2776694085 @default.
• W1985608906 hasConcept C2776802502 @default.
• W1985608906 hasConcept C2777063308 @default.
• W1985608906 hasConcept C2777511904 @default.
• W1985608906 hasConcept C2777909004 @default.
• W1985608906 hasConcept C2778239845 @default.
• W1985608906 hasConcept C2778850193 @default.
• W1985608906 hasConcept C2780350996 @default.
• W1985608906 hasConcept C31760486 @default.
• W1985608906 hasConcept C526805850 @default.
• W1985608906 hasConcept C530470458 @default.
• W1985608906 hasConcept C71924100 @default.
• W1985608906 hasConcept C90924648 @default.

• next